Antidepressant side effects differ greatly depending on the drug, study finds
Doctors have long known that antidepressants come with side effects for cardiovascular and metabolic health.
But a major analysis from a team of researchers in the U.K. has, for the first time, pulled together data from more than 150 clinical trials to compare the physical side effects of dozens of antidepressants.
The study, published in the Lancet this week, details how each medication can affect weight, blood pressure, heart rate, cholesterol and other areas of health.
The end result is something akin to a “sports league table” for 30 different antidepressants based on their side effect profile, says lead author Dr. Toby Pillinger, a psychiatrist at King’s College London.
“It’s never been done at this scale before and no one’s ever put specific numbers to the amount of weight you’ll put on, or to the amount that your cholesterol goes up,” he says.
The findings are based on existing data, mostly from 8-week drug studies, that altogether represent more than 58,000 patients.
The most frequently prescribed antidepressants in the U.S. — Selective Serotonin Reuptake Inhibitors, or SSRIs, like Zoloft and Prozac — tended to have fewer physical side effects, according to the analysis.
Other medications, particularly some of the older drugs, were shown to have more significant impacts.
For example, a person who took nortriptyline, a tricyclic antidepressant, could, on average, have an increase in heart rate that was 20 beats higher than the SSRI fluvoxamine. For other medications, the expected weight change could be four pounds gained, or lost.
Pillinger says the intention is not to single out certain antidepressants as better than others.
“It may be that one medication which is pretty bad for one person actually is pretty good for another one. I think that is the message, rather than naming and shaming certain drugs,” he says.
Pillinger hopes the data can help prescribers and their patients make individualized decisions about the best medication.
In fact, he and his colleagues have created a free digital tool that’s already being used by clinicians all over the world to create a “menu” of options, based on a patient’s underlying health and what side effects they’d most like to avoid.
Dr. Nina Kraguljac, a professor at the Ohio State University, who was not involved in the research, says the study was well-done — and largely reassuring.
“What surprised me about this study is that side effects are not that severe,” says Kraguljac, who is also chair of the American Psychiatric Association’s council on research.
However, she stresses that “side effects alone should not guide a clinical decision,” since the study’s results ultimately reflect an average, not the individual patient.
“Side effects do not happen in every patient and are not necessarily a reason to deter people from taking the medications,” she says.
The study does have some notable limitations.
Even though many people take these drugs for months or years, the data was largely from 8-week randomized controlled trials, which are the most common.
And some prominent side effects — that cause some people to stop taking antidepressants — were not evaluated, says Dr. David Hellerstein, a professor of psychiatry at Columbia University.
He points out the impact on sexual function, gastrointestinal issues, and “emotional blunting” — a sense that feelings are being muted — are all common complaints that weren’t looked at.
Most of the side effects detailed in the study are already well-known, although he believes the work will still be “a useful touchstone” for patients and prescribers.
“Big picture, most of these drugs seem quite safe on a lot of physical parameters, especially the newer drugs, like the SSRIs and SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors),” he says.
But for some groups of people, the side effects might be significant, he cautions, “and could affect what medicine the doctor would choose or what medicine a patient would prefer.”
And he notes, side effects aren’t always a downside.
Hellerstein has a patient who had lost a significant amount of weight due to depression, meaning an antidepressant that also led to some extra weight would actually be “healthy.”
“I would say that is not a side effect. That is a benefit of treatment,” he says.
The Gulf States Newsroom is hiring an Audio Editor
The Gulf States Newsroom is hiring an Audio Editor to join our award-winning team covering important regional stories across Mississippi, Alabama and Louisiana.
Judge orders new Alabama Senate map after ruling found racial gerrymandering
U.S. District Judge Anna Manasco, appointed by President Donald Trump during his first term, issued the ruling Monday putting a new court-selected map in place for the 2026 and 2030 elections.
Construction on Meta’s largest data center brings 600% crash spike, chaos to rural Louisiana
An investigation from the Gulf States Newsroom found that trucks contracted to work at the Meta facility are causing delays and dangerous roads in Holly Ridge.
Bessemer City Council approves rezoning for a massive data center, dividing a community
After the Bessemer City Council voted 5-2 to rezone nearly 700 acres of agricultural land for the “hyperscale” server farm, a dissenting council member said city officials who signed non-disclosure agreements weren’t being transparent with citizens.
Alabama Public Television meeting draws protesters in Birmingham over discussion of disaffiliating from PBS
Some members of the Alabama Educational Television Commission, which oversees APT, said disaffiliation is needed because the network has to cut costs after the Trump administration eliminated all funding for public media this summer.
Gov. Kay Ivey urges delay on PBS decision by public TV board
The Republican governor sent a letter to the Alabama Educational Television Commission ahead of a Nov. 18 meeting in which commissioners were expected to discuss disaffiliation.

